Literature DB >> 24996492

Clinical and genetic analysis in alternating hemiplegia of childhood: ten new patients from Southern Europe.

Marta Vila-Pueyo1, Roser Pons2, Miquel Raspall-Chaure1, Anna Marcé-Grau1, Oriel Carreño3, Cèlia Sintas3, Bru Cormand3, Mercè Pineda-Marfà4, Alfons Macaya5.   

Abstract

Alternating hemiplegia of childhood (AHC) is a rare neurodevelopmental disorder featuring attacks of hemiplegia and other paroxysmal and non-paroxysmal manifestations leading to progressive neurological impairment. De novo mutations in ATP1A3 have been identified in up to 80% of patients. AHC is also associated with rare mutations in other genes involved in episodic neurological disorders. We sought to find mutations in ATP1A3, CACNA1A, ATP1A2, SCN1A and SLC2A1 in a cohort of ten unrelated patients from Spain and Greece. All patients fulfilled AHC diagnostic criteria. All five genes were amplified by PCR and Sanger sequenced. Copy number variation (CNV) analysis of SLC2A1 and CACNA1A was performed using two different approaches. We identified three previously described heterozygous missense ATP1A3 mutations (p.Asp801Asn, p.Glu815Lys and p.Gly947Arg) in five patients. No disease-causing mutations were found in the remaining genes. All mutations occurred de novo; carriers presented on average earlier than non-carriers. Intellectual disability was more severe with the p.Glu815Lys variant. A p.Gly947Arg carrier harbored a maternally-inherited CACNA1A p.Ala454Thr variant. Of note, three of our patients exhibited remarkable clinical responses to the ketogenic diet. We confirmed ATP1A3 mutations in half of our patients. Further AHC genetic studies will need to investigate large rearrangements in ATP1A3 or consider greater genetic heterogeneity than previously suspected.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATP1A3; Alternating hemiplegia of childhood; CACNA1A; Genetics; Ketogenic diet; Neurodevelopmental syndrome

Mesh:

Substances:

Year:  2014        PMID: 24996492     DOI: 10.1016/j.jns.2014.06.014

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

Review 1.  Diagnosis and Treatment of Alternating Hemiplegia of Childhood.

Authors:  Melanie Masoud; Lyndsey Prange; Jeffrey Wuchich; Arsen Hunanyan; Mohamad A Mikati
Journal:  Curr Treat Options Neurol       Date:  2017-02       Impact factor: 3.598

2.  Alternating Hemiplegia of Childhood: Retrospective Genetic Study and Genotype-Phenotype Correlations in 187 Subjects from the US AHCF Registry.

Authors:  Louis Viollet; Gustavo Glusman; Kelley J Murphy; Tara M Newcomb; Sandra P Reyna; Matthew Sweney; Benjamin Nelson; Frederick Andermann; Eva Andermann; Gyula Acsadi; Richard L Barbano; Candida Brown; Mary E Brunkow; Harry T Chugani; Sarah R Cheyette; Abigail Collins; Suzanne D DeBrosse; David Galas; Jennifer Friedman; Lee Hood; Chad Huff; Lynn B Jorde; Mary D King; Bernie LaSalle; Richard J Leventer; Aga J Lewelt; Mylynda B Massart; Mario R Mérida; Louis J Ptáček; Jared C Roach; Robert S Rust; Francis Renault; Terry D Sanger; Marcio A Sotero de Menezes; Rachel Tennyson; Peter Uldall; Yue Zhang; Mary Zupanc; Winnie Xin; Kenneth Silver; Kathryn J Swoboda
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

3.  Gross Motor Function Disorders in Patients with Alternating Hemiplegia of Childhood.

Authors:  Agnieszka Stępień; Katarzyna Maślanko; Maciej Krawczyk; Witold Rekowski; Anna Kostera-Pruszczyk
Journal:  J Mother Child       Date:  2020-07-29

4.  A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood.

Authors:  Elodie Hainque; Samantha Caillet; Sandrine Leroy; Constance Flamand-Roze; Isaac Adanyeguh; Fanny Charbonnier-Beaupel; Maryvonne Retail; Benjamin Le Toullec; Mariana Atencio; Sophie Rivaud-Péchoux; Vanessa Brochard; Florence Habarou; Chris Ottolenghi; Florence Cormier; Aurélie Méneret; Marta Ruiz; Mohamed Doulazmi; Anne Roubergue; Jean-Christophe Corvol; Marie Vidailhet; Fanny Mochel; Emmanuel Roze
Journal:  Orphanet J Rare Dis       Date:  2017-10-02       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.